Posted On: Tuesday, February 14th, 2017
Things are already busy! Thanks for helping support and grow the MHI community by spreading the word of our services and events – together it’s amazing what we can accomplish! Keeping you up to date with MHI and community events is a part of this e-newsletter, so scroll on down and read about funding, testing,… Read more »
Posted On: Tuesday, January 17th, 2017
The third progress report of From Hope to Health: Towards an AIDS Free Generation is now available. This progress report from the Ministry of Health covers the third fiscal year of provincial expansion (April 1, 2015 – March 31, 2016). In addition, there is a supporting technical document with the source data and the parameters… Read more »
Posted On: Monday, December 12th, 2016
Please find attached the combined summary of the engagement process on refreshing the Ministry’s strategic policy related to viral hepatitis (Healthy Pathways Forward) that took place late 2015 and early 2016. Between November 25, 2015 to January 20, 2016 the Ministry of Health (the Ministry), the BC Centre for Disease Control BCCDC) and the BC… Read more »
Posted On: Tuesday, September 13th, 2016
Sep 09, 2016 04:35 pm | Deb Schmitz The BC Centre for Disease Control (BCCDC) has created a health database “…to assess and monitor disease burden, co-infections, disparities in testing and care, health care utilization, treatment uptake and completion, effectiveness of treatments, cost of hepatitis C-related illness and the impact of treatment on illness related… Read more »
Posted On: Monday, September 12th, 2016
Hope you will enjoy HepCBC’s SUMMER, 2016 hepc.bull newsletter. This is our LAST NEWSLETTER to you in this format as we are transitioning to sending all of our news out via our website, Facebook site, and You Tube Channel. It’s been over 20 years, and we are so proud of what our bulletin has accomplished and the many lives it has touched,… Read more »
Posted On: Thursday, September 1st, 2016
ViiV Healthcare Positive Action Canada HIV/AIDS Innovation Program (PACIP) 2016 Program Overview The 2016 Positive Action Canada HIV/AIDS Innovation Program (PACIP) Call for Proposals is seeking community-based initiatives that improve outcomes for people living with HIV/AIDS (PHAs) in Canada, and increase knowledge transfer and exchange of best practices amongst organizations working in the Canadian HIV… Read more »
Posted On: Tuesday, August 30th, 2016
The widespread availability of potent anti-HIV therapy (commonly called ART) in Canada and other high-income countries has had a tremendous impact on the health of HIV-positive people. Many ART users have had an increase in their life expectancy. The power of ART is so profound that researchers increasingly expect that a young adult who becomes… Read more »
Posted On: Tuesday, August 9th, 2016
New and noteworthy CATIE News: Liver cancer rates low in people with HIV and hepatitis C People with HIV and hepatitis C coinfection have low rates of liver cancer (about 1%), reported researchers in Clinical Infectious Diseases. This study drew information from four databases of people coinfected with HIV and hepatitis C and included 7,229… Read more »
Posted On: Tuesday, August 2nd, 2016
The “Hepatitis C Treatment Options: Basic Information for Patients” is now available directly on the Hepatitis Education Canada website. The tool allows people to input information about their own: • Genotype • treatment history, and • cirrhosis status to display selected CASL & AASLD recommended treatments. Also included on site are videos to help people… Read more »
Posted On: Monday, July 25th, 2016
by Susan Holtzman, Associate Professor of Psychology, University of British Columbia Okanagan campus Background Men who have sex with men (MSM) represent almost half of new HIV infections in Canada each year. However, the vast majority of research on HIV testing among MSM has been conducted in major urban centres. The main objectives of this… Read more »
Posted On: Monday, July 25th, 2016
On July 11, 2016, Health Canada licensed the sale and use of a new fixed-dose combination of two anti-hepatitis C virus (HCV) drugs sold under the brand name Epclusa and made by the pharmaceutical company Gilead Sciences. Epclusa contains the following medicines: sofosbuvir – 400 mg velpatasvir – 100 mg Clinical trials In clinical trials,… Read more »
Posted On: Monday, July 4th, 2016
During the 2014 Canadian Alliance to End Homelessness conference in Vancouver, a group of individuals came together with a common goal: to ensure that individuals with lived experience received equitable representation from service providers, researchers, policy makers, and others, so that they can better understand and tackle the problem of homelessness. To that end, the… Read more »
